Published in J Am Acad Dermatol on August 15, 2007
Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis | NCT02644954
Antibodies to watch in 2010. MAbs (2010) 1.90
Kruppel-like factor KLF4 facilitates cutaneous wound healing by promoting fibrocyte generation from myeloid-derived suppressor cells. J Invest Dermatol (2015) 1.44
Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci (2010) 1.41
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol (2010) 1.10
Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology (2012) 1.07
Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. Br J Pharmacol (2012) 1.06
Ustekinumab. Nat Rev Drug Discov (2009) 1.02
Update on the natural history and systemic treatment of psoriasis. Adv Dermatol (2008) 0.96
IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine (2013) 0.95
The dichotomous pattern of IL-12r and IL-23R expression elucidates the role of IL-12 and IL-23 in inflammation. PLoS One (2014) 0.93
Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity. J Inflamm (Lond) (2010) 0.85
Cardiovascular comorbiditiy in psoriasis. Indian J Dermatol (2011) 0.83
Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer. J Biomed Biotechnol (2012) 0.82
Inhibition of secretion of interleukin (IL)-12/IL-23 family cytokines by 4-trifluoromethyl-celecoxib is coupled to degradation via the endoplasmic reticulum stress protein HERP. J Biol Chem (2010) 0.81
Comprehensive sequence analysis of the human IL23A gene defines new variation content and high rate of evolutionary conservation. DNA Res (2010) 0.80
Ustekinumab in the therapy of chronic plaque psoriasis. Biologics (2009) 0.79
Isothiocyanates inhibit psoriasis-related proinflammatory factors in human skin. Inflamm Res (2012) 0.79
Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. Clin Cosmet Investig Dermatol (2009) 0.75
Interleukin-12, interleukin-23, and psoriasis: ABT-874 in clinical trials. J Am Acad Dermatol (2008) 0.75
Biologics in the management of psoriasis. Clin Cosmet Investig Dermatol (2009) 0.75
Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid (2010) 0.75
Deficiency of KLF4 compromises the lung function in an acute mouse model of allergic asthma. Biochem Biophys Res Commun (2017) 0.75
Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol (2010) 8.55
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol (2008) 3.95
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc (2004) 3.40
Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol (2003) 3.22
Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04
Adherence, the fourth dimension in the geometry of dermatological treatment. Arch Dermatol (2009) 2.91
In the United States, blacks and Asian/Pacific Islanders are more likely than whites to seek medical care for atopic dermatitis. Arch Dermatol (2002) 2.75
The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol (2005) 2.26
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol (2004) 2.05
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol (2004) 1.94
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol (2009) 1.94
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol (2009) 1.76
The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol (2005) 1.68
Adherence in dermatology: a review of the last 20 years. J Dermatolog Treat (2006) 1.64
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
Drug samples in dermatology: special considerations and recommendations for the future. J Am Acad Dermatol (2010) 1.55
Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol (2010) 1.53
Written action plans: potential for improving outcomes in children with atopic dermatitis. J Am Acad Dermatol (2008) 1.52
Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol (2007) 1.51
A randomized controlled pilot study of the effects of an extra office visit on adherence and outcomes in atopic dermatitis. Arch Dermatol (2010) 1.50
Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol (2007) 1.50
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol (2009) 1.48
UV light abuse as a substance-related disorder: clinical implications. Arch Dermatol (2008) 1.48
Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol (2004) 1.45
Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol (2005) 1.45
Trends in pediatric psoriasis outpatient health care delivery in the United States. Arch Dermatol (2011) 1.44
Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol (2006) 1.44
Hyperpigmentation: an overview of the common afflictions. Dermatol Nurs (2004) 1.43
Treatment of psoriasis in children: is there a role for antibiotic therapy and tonsillectomy? Pediatr Dermatol (2003) 1.43
Dermatosis neglecta: a series of case reports and review of other dirty-appearing dermatoses. Dermatol Online J (2006) 1.42
Trends in Mohs surgery from 1995 to 2010: an analysis of nationally representative data. Dermatol Surg (2015) 1.42
Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol (2005) 1.42
How much of a topical agent should be prescribed for children of different sizes? J Dermatolog Treat (2006) 1.40
Adherence with topical treatment is poor compared with adherence with oral agents: implications for effective clinical use of topical agents. J Am Acad Dermatol (2006) 1.40
Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners. J Am Acad Dermatol (2006) 1.40
Increase in procedures performed at dermatology office visits from 1995 to 2001. Dermatol Surg (2005) 1.39
Where did current academic dermatologists train? J Am Acad Dermatol (2010) 1.39
Phototherapy trends in dermatology. J Dermatolog Treat (2013) 1.38
Use of electronic medical records differs by specialty and office settings. J Am Med Inform Assoc (2013) 1.34
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol (2007) 1.34
Quality of life in patients with psoriasis. Health Qual Life Outcomes (2006) 1.31
Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis (2002) 1.27
The safety of liposuction: results of a national survey. Dermatol Surg (2002) 1.25
Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics (2009) 1.24
Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis (2010) 1.22
The economic impact of non-melanoma skin cancer: a review. J Natl Compr Canc Netw (2010) 1.20
The effect of reminder systems on patients' adherence to treatment. Patient Prefer Adherence (2012) 1.19
Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache (2003) 1.19
Tanning as an addictive behavior: a literature review. Photodermatol Photoimmunol Photomed (2009) 1.19
Correlates of patient satisfaction with physician visit: differences between elderly and non-elderly survey respondents. Health Qual Life Outcomes (2007) 1.18
Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol (2004) 1.17
What specialties perform the most common outpatient cosmetic procedures in the United States? Dermatol Surg (2007) 1.17
Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol (2005) 1.16
Medical adherence to acne therapy: a systematic review. Am J Clin Dermatol (2014) 1.15
The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat (2005) 1.14
A review of targeted ultraviolet B phototherapy for psoriasis. J Am Acad Dermatol (2011) 1.12
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol (2010) 1.10
Lower adverse event and mortality rates in physician offices compared with ambulatory surgery centers: a reappraisal of Florida adverse event data. Dermatol Surg (2004) 1.09
Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother (2006) 1.08
Tangential shave removal of basal cell carcinoma. Dermatol Surg (2013) 1.08
Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol (2012) 1.08
A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother (2011) 1.08
Alopecia in the United States: outpatient utilization and common prescribing patterns. J Am Acad Dermatol (2007) 1.08
Frequency and cost of actinic keratosis treatment. Dermatol Surg (2006) 1.07
Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol (2005) 1.07
Consensus guidelines for the management of plaque psoriasis. Arch Dermatol (2012) 1.06
Acne in adolescents: quality of life, self-esteem, mood, and psychological disorders. Dermatol Online J (2011) 1.06
Psoriasis and pregnancy. J Cutan Med Surg (2002) 1.05
Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol (2012) 1.03
Pachydermodactyly from repetitive motion in poultry processing workers: a report of 2 cases. Arch Dermatol (2012) 1.03
Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol (2004) 1.03
American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol (2004) 1.03
The negative impact of psoriasis on the workplace. J Dermatolog Treat (2006) 1.03
A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J (2004) 1.02
Acne vulgaris and depression: a retrospective examination. J Cosmet Dermatol (2010) 1.01
Melasma and its impact on health-related quality of life in Hispanic women. J Dermatolog Treat (2007) 1.00
Vision problems, eye care history, and ocular protection among migrant farmworkers. Arch Environ Occup Health (2008) 1.00
What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med (2006) 0.99
Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother (2009) 0.98
Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials. JAMA Dermatol (2013) 0.98
Correlates of health-related quality of life in women with severe facial blemishes. Int J Dermatol (2006) 0.98
Hyperpigmentation: a review of common treatment options. J Drugs Dermatol (2004) 0.97
Treatment patterns and cost of nonmelanoma skin cancer management. Dermatol Surg (2006) 0.97
Psoralen plus ultraviolet A light phototherapy effectiveness. J Am Acad Dermatol (2010) 0.96
Nonmelanoma skin cancer: an episode of care management approach. Dermatol Surg (2003) 0.96
Acne vulgaris in the United States: a descriptive epidemiology. Cutis (2010) 0.95
Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol (2003) 0.94
Effect of patient satisfaction on outcomes of care. Expert Rev Pharmacoecon Outcomes Res (2009) 0.94
Ultraviolet tanning addiction. Dermatol Clin (2009) 0.94
Seasonal variation of dermatologic disease in the USA: a study of office visits from 1990 to 1998. Int J Dermatol (2004) 0.94
Side effects of common acne treatments. Expert Opin Drug Saf (2012) 0.94
Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv (2012) 0.94
The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat (2013) 0.94
Acitretin in dermatology: a review. J Drugs Dermatol (2011) 0.93
Nonmelanoma skin cancer: is the incidence really increasing among patients younger than 40? A reexamination using 25 years of U.S. outpatient data. Dermatol Surg (2006) 0.93
Adverse event reporting: lessons learned from 4 years of Florida office data. Dermatol Surg (2005) 0.93
Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol (2009) 0.92